- Email: [email protected]
5352458 Tanning method using DNA repair liposomes
Healthcare Products
5352446
5352450
M E T H O D OF TREATING DENTAL CARIES WITH M O N O C L O N A L ANTIBODIES AGAINST THE ANTIGEN I A N D ANTIGEN I/II OF STREPTOCOCCUS MUTANS
M E T H O D FOR PREPARING VACCINE FOR DENTAL CARIES AND VACCINAL C O M P O S I T I O N S FOR DENTAL CARIES U S E D AS NASAL D R O P Toshihiko Koga, Nobuo Okahashi, Ichiro Takahashi, Koji Shibuya, Hirotaka Ohta, Tokyo, Japan assigned to Lion Corporation; National Institute of Heal
Thomas Lehner, Barnet, United Kingdom assigned to Council of Governors of the United Medical and Dental Schools of Guy's and St Thomas's Hospitals
A method for preparing a vaccine for dental caries comprises the step of culturing a variant which is obtained by integrating a protein antigen (PAc)-expressing gene into the chromosomal gene of a Streptococcus mutans GS-5 strain to obtain the protein antigen, the protein antigen being produced on the surface of cells of oral Streptococcus mutans or it being extracellularly produced by the microorganism and having a molecular weight ranging from about 170,000 to 220,000. Streptococcus mutaus GS-5 (K-3), in which a protein antigenexpressing gene is integrated into the chromosomal gene thereof, has an ability of producing the protein antigen on the surface of the cells or extracellularly. A preventive vaccine composition for dental caries for nasal drops comprises the protein antigen thus produced by the strain: Strep~ mutans, the vaccine being intranasally administered. The method makes it possible to enhance the yield of PAc and to simplify processes for purifying. PAc. The vaccine composition makes-it possthle to internally easily absorb the protein antigen, PAc, in high efficiency and it also makes it possible to effectively increase the antibody titer observed after the administration thereof.
A method of combatting dental caries in a mammal comprises topical application to a surface of a tooth in the mammals mouth of a monoclonal antibody raised against antigen I or antigen I/iI of Streptococcus mutans serotype c.
5352447 I M M U N O T O X I N S FOR TREATMENT OF INTRACRANIAL LESIONS A N D AS A D J U N C T TO CHEMOTHERAPY Virginia Johnson, Richard J Youle assigned to The United States of America as represented by the Secretary of the Department of Health and Human Services A potent and specific immunotoxin is prepared by coupling a binding-site inactivated diphtheria toxin (CRM 107) to a new binding moiety consisting of transferrin or a monoclonal antibody against the human transferrin receptor. These immunotoxins are minor specific and lack the nonspecific toxicity produced by the binding activity of the native toxin. The immunotoxin is useful in treating primary brain tumors, metastatic tmnors to the brain, CSFborne tumors, leptomeningeal leukemia and leptomeningeal carcinomatosis.
5352458 TANNING M E T H O D USING DNA REPAIR L I P O S O M E S Daniel B Yarosh assigned to Applied Genetics Inc 303
304
PATENT ABSTRACTS
A method for tanning skin is provided in which liposomes containing a DNA repair enzyme are administered to skin in combination with exposure of the skin to UV radiation. The result is an enhanced level of melanin production, i.e., more tanning than achieved by UV radiation alone. The administration of the DNA repair enzymes in liposomes also reduces the level of DNA damage caused by the UV exposure. Accordingly, both the tanning response is increased and the deleterious effect of UV exposure is decreased. The method can be used by the general population as well as by individuals whose skin is susceptible to UVinduced damage.
5352584 MONOCLONAL ANTIBODIES WHICH BIND (E)-5-(2BROMOVINYL)ARABINOFURANOSYLURACIL AND DIAGNOSTIC METHODS BASED THEREON Edward M Croze, Jan-I Tu, Marc D Ogan assigned to E R Squibb & Sons Inc Monoclonal antibodies which bind (E)-5(2bromovinyl)-arabino furanosyluracil and/or immunologic.ally related compounds, hybrid cell lines which produce these monoclonal antibodies, and immunoassay methods for detecting (E)-5-(2-bromovinyl)-arabinofuranosyluracil and/or immunologic.ally related compounds usingthese monoclonal antibodies.
5352586 5352583 HUMAN TISSUE PLASMINOGEN ACTIVATORHUMAN PLASMINOGEN ACTIVATOR INHIBITOR COMPLEX IMMUNOASSAY AND KIT THEREFOR Yoich Sakata, Kazuhik Itoh, Shuicbiro Hino, Ryoich Hasegawa, Naomi Okamoto, Atsushi Noro, Toshm'"ob Murakami, Utsunomiya, Japan assigned to Teijin Limited A kit for the immunological assay of the human tissue pla~minogen activator-human plasminogen activator inhibitor complex in a human specimen, which kit comprises 0) a monoclonal antibody (first antibody) against a human plasminogen activator inhibitor linked onto an insoluble solid carrier having a specular surface, (ii) a polyclonal antibody (second antibody) against a bureau tissue plasminogen activator labelled by an enzyme, Cfii) a substrate and a reaction-discontinuing agent for the assay of the enzyme activity, (iv) a diluent, and (v) a detergent containing a nonionic surfactant having an HLB (Hydrophile Lipophile Balance) value of at least 16, and a method for the immunological assay of the above complex and a method for the immunological assay of the active human plasminogen activator inhibitor, respectively in a human specimen using this kit.
METHOD OF DETERMINING THE PRESENCE OF AN ANTIBIOTIC PRODUCED BY LACTOBACILLUS REUTERI Walter J Dobrogosz, Sven E Lindgren assigned to Biogaia AB The antibiotic reuterin is obtained by cultivating strains of Lactobacillus reuteri under controlled conditions. Reuterin has inhibitory activity against Gram positive and Gram negative bacteria, against yeast, Saccharomyces cerevisiae, and against the protozoan, Trypanosoma cruzi. Reuterin producing strains are identified by grown inhibition of susceptible microorganisms in the presence of glycerol or giyceraldehyde.
5352587 COMPOSITIONS AND METHODS FOR THE SYNTHESIS OF NATRIURETIC PROTEIN RECEPTOR B AND METHODS OF USE Ming-Sh Chang, David V Goeddel, David G Lowe, Newbury Park, Canada assigned to Genentech Inc Described are the amino acid sequence of natriuretic peptide receptor B ( N P R B ) a n d DNA encoding NPRB. Also disclosed are expression vectors and cells transformed to
5352446
5352450
M E T H O D OF TREATING DENTAL CARIES WITH M O N O C L O N A L ANTIBODIES AGAINST THE ANTIGEN I A N D ANTIGEN I/II OF STREPTOCOCCUS MUTANS
M E T H O D FOR PREPARING VACCINE FOR DENTAL CARIES AND VACCINAL C O M P O S I T I O N S FOR DENTAL CARIES U S E D AS NASAL D R O P Toshihiko Koga, Nobuo Okahashi, Ichiro Takahashi, Koji Shibuya, Hirotaka Ohta, Tokyo, Japan assigned to Lion Corporation; National Institute of Heal
Thomas Lehner, Barnet, United Kingdom assigned to Council of Governors of the United Medical and Dental Schools of Guy's and St Thomas's Hospitals
A method for preparing a vaccine for dental caries comprises the step of culturing a variant which is obtained by integrating a protein antigen (PAc)-expressing gene into the chromosomal gene of a Streptococcus mutans GS-5 strain to obtain the protein antigen, the protein antigen being produced on the surface of cells of oral Streptococcus mutans or it being extracellularly produced by the microorganism and having a molecular weight ranging from about 170,000 to 220,000. Streptococcus mutaus GS-5 (K-3), in which a protein antigenexpressing gene is integrated into the chromosomal gene thereof, has an ability of producing the protein antigen on the surface of the cells or extracellularly. A preventive vaccine composition for dental caries for nasal drops comprises the protein antigen thus produced by the strain: Strep~ mutans, the vaccine being intranasally administered. The method makes it possible to enhance the yield of PAc and to simplify processes for purifying. PAc. The vaccine composition makes-it possthle to internally easily absorb the protein antigen, PAc, in high efficiency and it also makes it possible to effectively increase the antibody titer observed after the administration thereof.
A method of combatting dental caries in a mammal comprises topical application to a surface of a tooth in the mammals mouth of a monoclonal antibody raised against antigen I or antigen I/iI of Streptococcus mutans serotype c.
5352447 I M M U N O T O X I N S FOR TREATMENT OF INTRACRANIAL LESIONS A N D AS A D J U N C T TO CHEMOTHERAPY Virginia Johnson, Richard J Youle assigned to The United States of America as represented by the Secretary of the Department of Health and Human Services A potent and specific immunotoxin is prepared by coupling a binding-site inactivated diphtheria toxin (CRM 107) to a new binding moiety consisting of transferrin or a monoclonal antibody against the human transferrin receptor. These immunotoxins are minor specific and lack the nonspecific toxicity produced by the binding activity of the native toxin. The immunotoxin is useful in treating primary brain tumors, metastatic tmnors to the brain, CSFborne tumors, leptomeningeal leukemia and leptomeningeal carcinomatosis.
5352458 TANNING M E T H O D USING DNA REPAIR L I P O S O M E S Daniel B Yarosh assigned to Applied Genetics Inc 303
304
PATENT ABSTRACTS
A method for tanning skin is provided in which liposomes containing a DNA repair enzyme are administered to skin in combination with exposure of the skin to UV radiation. The result is an enhanced level of melanin production, i.e., more tanning than achieved by UV radiation alone. The administration of the DNA repair enzymes in liposomes also reduces the level of DNA damage caused by the UV exposure. Accordingly, both the tanning response is increased and the deleterious effect of UV exposure is decreased. The method can be used by the general population as well as by individuals whose skin is susceptible to UVinduced damage.
5352584 MONOCLONAL ANTIBODIES WHICH BIND (E)-5-(2BROMOVINYL)ARABINOFURANOSYLURACIL AND DIAGNOSTIC METHODS BASED THEREON Edward M Croze, Jan-I Tu, Marc D Ogan assigned to E R Squibb & Sons Inc Monoclonal antibodies which bind (E)-5(2bromovinyl)-arabino furanosyluracil and/or immunologic.ally related compounds, hybrid cell lines which produce these monoclonal antibodies, and immunoassay methods for detecting (E)-5-(2-bromovinyl)-arabinofuranosyluracil and/or immunologic.ally related compounds usingthese monoclonal antibodies.
5352586 5352583 HUMAN TISSUE PLASMINOGEN ACTIVATORHUMAN PLASMINOGEN ACTIVATOR INHIBITOR COMPLEX IMMUNOASSAY AND KIT THEREFOR Yoich Sakata, Kazuhik Itoh, Shuicbiro Hino, Ryoich Hasegawa, Naomi Okamoto, Atsushi Noro, Toshm'"ob Murakami, Utsunomiya, Japan assigned to Teijin Limited A kit for the immunological assay of the human tissue pla~minogen activator-human plasminogen activator inhibitor complex in a human specimen, which kit comprises 0) a monoclonal antibody (first antibody) against a human plasminogen activator inhibitor linked onto an insoluble solid carrier having a specular surface, (ii) a polyclonal antibody (second antibody) against a bureau tissue plasminogen activator labelled by an enzyme, Cfii) a substrate and a reaction-discontinuing agent for the assay of the enzyme activity, (iv) a diluent, and (v) a detergent containing a nonionic surfactant having an HLB (Hydrophile Lipophile Balance) value of at least 16, and a method for the immunological assay of the above complex and a method for the immunological assay of the active human plasminogen activator inhibitor, respectively in a human specimen using this kit.
METHOD OF DETERMINING THE PRESENCE OF AN ANTIBIOTIC PRODUCED BY LACTOBACILLUS REUTERI Walter J Dobrogosz, Sven E Lindgren assigned to Biogaia AB The antibiotic reuterin is obtained by cultivating strains of Lactobacillus reuteri under controlled conditions. Reuterin has inhibitory activity against Gram positive and Gram negative bacteria, against yeast, Saccharomyces cerevisiae, and against the protozoan, Trypanosoma cruzi. Reuterin producing strains are identified by grown inhibition of susceptible microorganisms in the presence of glycerol or giyceraldehyde.
5352587 COMPOSITIONS AND METHODS FOR THE SYNTHESIS OF NATRIURETIC PROTEIN RECEPTOR B AND METHODS OF USE Ming-Sh Chang, David V Goeddel, David G Lowe, Newbury Park, Canada assigned to Genentech Inc Described are the amino acid sequence of natriuretic peptide receptor B ( N P R B ) a n d DNA encoding NPRB. Also disclosed are expression vectors and cells transformed to